AbbVie Reports Third-Quarter 2026 Financial Results

{
  "signal_id": "c2dbbe80-20e6-6b0d-7207-ca9a9ebaf9e7",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-10-30T11:46:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2026-financial-results-302924866.html",
    "title": "AbbVie Reports Third-Quarter 2026 Financial Results",
    "ticker": "NYSE:ABBV",
    "excerpt": "NORTH CHICAGO, Ill. , Oct. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2026. \"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio,\" said Robert A. Michael, chairman and chief executive officer, AbbVie. \"We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.\" Third-Quarter Results Note: \"Operational\" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Recent Events Full-Year 2026 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted. AbbVie does not provide a reconciliation of...",
    "summary": "AbbVie completed the acquisition of Apogee Therapeutics.",
    "location": "North Chicago, Illinois, United States",
    "planning": false,
    "confidence": 0.95,
    "published_at": "2026-10-30T11:46:00Z",
    "location_data": [
      {
        "city": "North Chicago",
        "state": "Illinois",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "\"We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics.",
    "related_company_name": "Apogee Therapeutics",
    "related_company_domain": "apogeetherapeutics.com"
  }
}

curl https://signals.autobound.ai/v1/signals/c2dbbe80-20e6-6b0d-7207-ca9a9ebaf9e7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'